Important advances in oxurion's r&d program on geographic atrophy secondary to amd

` important advances in oxurion's r&d program on geographic atrophy secondary to amd leuven, belgium – may 6, 2024 – 6:00 pm cet, oxurion nv (euronext brussels: oxur), an innovative biopharmaceutical company based in leuven, today announces important progress in its preclinical program targeting geographic atrophy (ga), a severe and underserved form of age-related macular degeneration (amd). this recently launched program has reached the first step with the identification of 50 targets that have the potential to provide better treatment options for ga.
AMD Ratings Summary
AMD Quant Ranking